Search

everythinglearnresearchcommunity

for

Search:↓

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Women with PCOS may have a higher risk of severe COVID-19 due to hormonal imbalances and vitamin D deficiency.

Hair usually grows back 1-3 months after treatment for anagen effluvium, and children with Loose Anagen Hair Syndrome often improve by adolescence.

The protein StAR is found in 17 different organs and can affect hair loss and brain functions, but its full role is not yet fully understood.

New treatment combining PRP and SVF increases hair density in 6-12 weeks for androgenetic alopecia patients.

Searches for acne, hair loss, and eczema increased during COVID-19, while searches for other skin issues decreased.

Testosterone's effects on COVID-19 are unclear and need more research.

Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.

Some nutraceuticals may help in COVID-19 prevention and treatment, but more research is needed.

Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Certain types of rashes in COVID-19 patients may indicate more severe illness and higher risk of death.

Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.

Using mesenchymal stem cells or their exosomes is safe for COVID-19 patients and helps improve lung healing and oxygen levels.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

MSC-derived exosomes can help treat COVID-19, hair loss, skin aging, and arthritis.

New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Cepharanthine may help hair growth by increasing IGF-I in scalp cells.

Inflammasome proteins can indicate the severity and treatment response of various diseases and injuries.

New gene mutations linked to skin conditions were found, bacteria and chemicals may worsen acne, a dog mutation could exist in humans, virus-like elements might be involved in psoriasis, and a vitamin D3 treatment doesn't prevent chemotherapy-related hair loss.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Growth factors and cytokines are important for hair growth and could potentially treat hair loss, but more research is needed to overcome challenges before they can be used in treatments.

Herbs can potentially treat hair loss by inhibiting a key enzyme and promoting hair growth, and deficiencies in zinc, biotin, and iron are linked to hair loss.

Hair microRNAs could be effective biomarkers for diagnosing scleroderma.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Minoxidil, a common hair loss treatment, might work by counteracting a hormone that reduces hair growth and promotes hair loss.